Reuters logo
BRIEF-Gilead says presents data supporting efficacy and safety of Vemlidy in patients with chronic hepatitis B after 96 weeks
April 20, 2017 / 4:19 PM / 8 months ago

BRIEF-Gilead says presents data supporting efficacy and safety of Vemlidy in patients with chronic hepatitis B after 96 weeks

April 20 (Reuters) - Gilead Sciences Inc

* Gilead sciences inc says presents data supporting efficacy and safety of vemlidy in patients with chronic hepatitis b after 96 weeks Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below